What is the prevalence of pituitary adenoma?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 6, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Pituitary adenomas have a prevalence of approximately 1 in 1,000 people in the general population, with the prevalence increasing with age, and a slight female predominance, particularly for prolactinomas 1.

Prevalence of Pituitary Adenomas

The prevalence of pituitary adenomas is estimated to be around 1 in 1,000 people in the general population, with a higher prevalence in older adults and a slight female predominance, particularly for prolactinomas.

  • The prevalence of pituitary adenomas increases with age, with a significant increase in incidence during late adolescence, from 1% of all intracranial neoplasms before 15 years of age to 18% for patients aged 15–24 years 1.
  • Pituitary adenomas are relatively common, with an estimated prevalence of approximately 1 in 1,000 people in the general population, however, when including incidental findings from imaging studies, the prevalence may be as high as 10-20% of the population 1.

Clinically Significant Pituitary Adenomas

The prevalence of clinically significant pituitary adenomas that cause symptoms due to hormone overproduction or local mass effects is much lower, estimated at about 80-100 cases per million population.

  • Many pituitary adenomas are non-functioning and cause no symptoms, being discovered incidentally during brain imaging performed for unrelated reasons 1.
  • Pituitary adenomas have a high survival rate but might confer potentially serious, life-changing and life-limiting sequelae, and increase in incidence with increasing age over childhood, representing 78% of pituitary fossa lesions in children and young people under 19 years of age 1.

From the Research

Prevalence of Pituitary Adenoma

  • The prevalence of pituitary adenoma is estimated to be around 1 case per 1000 of the general population 2.
  • Epidemiologic studies show that pituitary adenomas are increasing in incidence (between 3.9 and 7.4 cases per 100,000 per year) and prevalence (76 to 116 cases per 100,000 population) in the general population 2.
  • Data from postmortem studies and imaging studies suggest that 1 of 5 individuals in the general population may have pituitary adenoma 3.
  • Pituitary adenomas account for about 15% of intracranial neoplasms 3.

Types of Pituitary Adenoma

  • The most common type of pituitary adenoma is prolactinoma 3, 4.
  • Clinically non-functioning pituitary adenomas (NFPAs) represent one-third of pituitary adenomas and do not secrete hormones 3.
  • Other types of pituitary adenomas include growth hormone (GH)-secreting adenomas, adrenocorticotropic hormone (ACTH)-secreting adenomas, and thyroid-stimulating hormone (TSH)-secreting adenomas 5, 4.

Incidence and Demographics

  • Most new cases diagnosed are prolactinomas and nonsecreting pituitary adenomas 2.
  • Most clinically relevant pituitary adenomas occur in females, but pituitary adenomas are clinically heterogeneous 2.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

The Epidemiology of Pituitary Adenomas.

Endocrinology and metabolism clinics of North America, 2020

Research

Diagnosis and treatment of pituitary adenomas.

Minerva endocrinologica, 2004

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.